Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dilip Sengupta

Orthopaedic Surgery Mansfield, TX Medical Doctor

NPI 1184656282 CMS profile 325374

1632 Piccadilly Ct, Suite 512, Mansfield, TX 76063

Open in the dashboard

General payments

$689,017

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dilip Sengupta of Mansfield, TX is reported in the CMS Open Payments database as having received $689,017 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $105,261 16
2024 General $99,539 17
2023 General $91,186 15
2022 General $88,473 16
2021 General $107,345 27
2020 General $101,638 13
2019 General $95,576 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dilip Sengupta
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Dilip Sengupta were reported at $105,261. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Dilip Sengupta Orthopaedic Surgery median Middle half National median
2019 $95,576 $644 $140–$2,844 $163
2020 $101,638 $312 $75–$1,860 $114
2021 $107,345 $520 $117–$2,495 $132
2022 $88,473 $598 $128–$2,731 $149
2023 $91,186 $461 $128–$2,264 $160
2024 $99,539 $497 $134–$2,475 $164
2025 $105,261 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CTL Medical Corporation $553,207 80 payments
  2. Globus Medical, Inc. $134,411 38 payments
  3. Brainlab, Inc. $1,130 1 payment
  4. Sanara MedTech Inc. $141 1 payment
  5. Stryker Corporation $74 1 payment
  6. Providence Medical Technology, Inc. $22 1 payment
  7. Baxter Healthcare $21 1 payment
  8. Radius Health, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $553,000 79 payments
  2. Royalty or License $134,139 34 payments
  3. Travel and Lodging $1,325 2 payments
  4. Food and Beverage $346 8 payments
  5. Gift $207 1 payment
Products named General payments · program years 2019–2025
  1. Spinal $308,207 45 payments
  2. Raphael Pedicle Screw System $84,000 12 payments
  3. TRANSITION Spine $37,423 6 payments
  4. CREO ADDITION $35,366 7 payments
  5. CREO Orthopedics/Orthopedic Surgery $21,261 4 payments
  6. CREO Spine $16,055 4 payments
  7. CREO Spine/Joint $15,000 4 payments
  8. TRANSITION Spine/Joint $4,778 4 payments
  9. SECURE-C $3,331 4 payments
  10. Image Guided Surgical Device $1,130 1 payment
  11. Other $1,444 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

189

Median for Orthopedic Surgery: 203

Drug cost

$34,189

Median for Orthopedic Surgery: $1,433

Branded share of claims

8.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Teriparatide Generic 16 $32,498
Diclofenac Sodium Generic 22 $554
Cyclobenzaprine Hcl Generic 34 $474
Ultra-Fine Mini Pen Needle Pen Needle, Diabetic Brand 16 $273
Alendronate Sodium Generic 21 $156
Meloxicam Generic 64 $123
Gabapentin Generic 16 $112

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$47,651

Medicare's payments for the services billed

Medicare patients

60

Average age 73

Services billed

255

38 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 42%
Ischemic heart disease 38%
Osteoporosis 37%
Depression 28%
Chronic kidney disease 25%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record